CA3087797A1 - Pharmaceutical combinations of egfr inhibitors and methods of use thereof - Google Patents

Pharmaceutical combinations of egfr inhibitors and methods of use thereof Download PDF

Info

Publication number
CA3087797A1
CA3087797A1 CA3087797A CA3087797A CA3087797A1 CA 3087797 A1 CA3087797 A1 CA 3087797A1 CA 3087797 A CA3087797 A CA 3087797A CA 3087797 A CA3087797 A CA 3087797A CA 3087797 A1 CA3087797 A1 CA 3087797A1
Authority
CA
Canada
Prior art keywords
egfr
optionally substituted
subject
need
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3087797A
Other languages
English (en)
French (fr)
Inventor
Nathanael S. Gray
Dries DE CLERCQ
Jaebong Jang
Pasi Janne
Ciric TO
Michael Eck
Eunyoung Park
David HEPPNER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of CA3087797A1 publication Critical patent/CA3087797A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3087797A 2018-02-20 2019-02-20 Pharmaceutical combinations of egfr inhibitors and methods of use thereof Pending CA3087797A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862632806P 2018-02-20 2018-02-20
US62/632,806 2018-02-20
US201862744083P 2018-10-10 2018-10-10
US62/744,083 2018-10-10
PCT/US2019/018774 WO2019164949A1 (en) 2018-02-20 2019-02-20 Pharmaceutical combinations of egfr inhibitors and methods of use thereof

Publications (1)

Publication Number Publication Date
CA3087797A1 true CA3087797A1 (en) 2019-08-29

Family

ID=67688573

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3087797A Pending CA3087797A1 (en) 2018-02-20 2019-02-20 Pharmaceutical combinations of egfr inhibitors and methods of use thereof

Country Status (6)

Country Link
US (1) US20210085688A1 (https=)
EP (1) EP3755337A4 (https=)
JP (1) JP2021514011A (https=)
AU (1) AU2019225807A1 (https=)
CA (1) CA3087797A1 (https=)
WO (1) WO2019164949A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021514011A (ja) * 2018-02-20 2021-06-03 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｅｇｆｒ阻害剤の組合せ医薬製剤およびその使用法
EP3755689B1 (en) 2018-02-20 2023-12-06 Dana-Farber Cancer Institute, Inc. Inhibitors of egfr and methods of use thereof
AU2019225799A1 (en) * 2018-02-20 2020-07-09 Dana-Farber Cancer Institute, Inc. Pharmaceutical combinations of EGFR inhibitors and methods of use thereof
CN114553638A (zh) 2018-09-15 2022-05-27 华为技术有限公司 一种通信方法、设备和系统
AU2022230397A1 (en) * 2021-03-02 2023-09-21 Dana-Farber Cancer Institute, Inc. Covalent egfr inhibitors and methods of use thereof
US20250197390A1 (en) * 2022-03-16 2025-06-19 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Fused heterocyclic compound, and preparation method therefor and medical use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070105835A1 (en) * 2005-11-07 2007-05-10 Kazantsev Aleksey G Compositions and methods for modulating poly(ADP-ribose) polymerase activity
CA2746220A1 (en) * 2008-12-08 2010-07-08 Vm Pharma Llc Compositions of protein receptor tyrosine kinase inhibitors
CN103702990B (zh) * 2011-07-27 2015-09-09 阿斯利康(瑞典)有限公司 2-(2,4,5-取代苯胺)嘧啶衍生物作为egfr调谐子用于治疗癌症
WO2014160430A1 (en) * 2013-03-13 2014-10-02 Georgetown University Small molecule lrrk2 and erk5 inhibitors
US20170114323A1 (en) * 2014-06-19 2017-04-27 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
EP3399968B8 (en) * 2016-01-07 2021-12-01 Xuanzhu Biopharmaceutical Co., Ltd. Selective inhibitors of clinically important mutants of the egfr tyrosine kinase
US11155556B2 (en) * 2016-04-07 2021-10-26 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods for treating PI3K-mediated disorders
JP2021514011A (ja) * 2018-02-20 2021-06-03 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｅｇｆｒ阻害剤の組合せ医薬製剤およびその使用法
AU2019225811A1 (en) * 2018-02-20 2020-07-09 Dana-Farber Cancer Institute, Inc. Degraders of EGFR and methods of use thereof
EP3755689B1 (en) * 2018-02-20 2023-12-06 Dana-Farber Cancer Institute, Inc. Inhibitors of egfr and methods of use thereof
US20200377477A1 (en) * 2018-02-20 2020-12-03 Dana-Farber Cancer Institute, Inc. Degraders of egfr and methods of use thereof

Also Published As

Publication number Publication date
JP2021514011A (ja) 2021-06-03
EP3755337A1 (en) 2020-12-30
AU2019225807A1 (en) 2020-07-02
US20210085688A1 (en) 2021-03-25
WO2019164949A1 (en) 2019-08-29
EP3755337A4 (en) 2021-11-03

Similar Documents

Publication Publication Date Title
CA3087288A1 (en) Inhibitors of egfr and methods of use thereof
EP3892272B1 (en) Bifunctional molecules for degradation of egfr and methods of use
US12161649B2 (en) Inhibitors of EGFR and methods of use thereof
EP3317273B1 (en) Inhibitors of egfr and methods of use thereof
CA3087797A1 (en) Pharmaceutical combinations of egfr inhibitors and methods of use thereof
WO2017223452A1 (en) Degradation of bromodomain-containing protein 9 (brd9) by conjugation of brd9 inhibitors with e3 ligase ligand and methods of use
EP3755689B1 (en) Inhibitors of egfr and methods of use thereof
US20210077469A1 (en) Pharmaceutical combinations of egfr inhibitors and methods of use thereof
US20200377501A1 (en) Degraders of egfr and methods of use thereof
CA3088561A1 (en) Degraders of egfr and methods of use thereof
CA3087800A1 (en) Pharmaceutical combinations of egfr inhibitors and methods of use thereof

Legal Events

Date Code Title Description
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250904

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251104

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260407